Dyne Therapeutics, Inc. (NYSE:DYN) has been given an average recommendation of “Buy” by the five analysts that are covering the stock, according to MarketBeat Ratings. Four investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $27.20.
Dyne Therapeutics has been the subject of a number of recent research reports. StockNews.com began coverage on Dyne Therapeutics with a “sell” rating for the company. JPMorgan Chase & Co. lifted their price objective on Dyne Therapeutics from $20.00 to $22.00 and gave the stock an “overweight” rating. Finally, Chardan Capital reiterated a “buy” rating and issued a $20.00 price objective on shares of Dyne Therapeutics.
Dyne Therapeutics opened at $8.79 on Friday. The stock has a 50-day simple moving average of $10.70 and a 200-day simple moving average of $11.38. The firm has a market capitalization of $536.37 million, a P/E ratio of -2.59, and a beta of 0.16. Dyne Therapeutics has a 52-week low of $8.04 and a 52-week high of $15.60.
Dyne Therapeutics last released its quarterly earnings data on Thursday, August 3rd. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.27). Analysts forecast that Dyne Therapeutics will post -3.57 earnings per share for the current year.
In other news, COO Susanna Gatti High sold 2,672 shares of Dyne Therapeutics stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $9.41, for a total transaction of $25,143.52. Following the sale, the chief operating officer now owns 104,544 shares of the company’s stock, valued at approximately $983,759.04.
Several institutional investors have recently made changes to their positions in DYN. EcoR1 Capital LLC purchased a new stake in shares of Dyne Therapeutics during the 4th quarter. VR Adviser LLC purchased a new stake in shares of Dyne Therapeutics during the 2nd quarter. State Street Corp raised its position in shares of Dyne Therapeutics by 196.2% during the 2nd quarter. Atlas Venture Life Science Advisors LLC raised its position in Dyne Therapeutics by 10.5% in the fourth quarter. Finally, Braidwell LP purchased a new stake in Dyne Therapeutics in the fourth quarter.
Dyne Therapeutics, Inc. is a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Before considering Dyne Therapeutics, investors should take note of the analysts’ “buy” recommendation and the current price target of $27.20. The company has recently released its quarterly earnings data, with earnings per share falling short of estimates. Insider transactions have also taken place, with the Chief Operating Officer selling shares of the company’s stock. Institutional investors have made changes to their positions in Dyne Therapeutics, indicating interest in the company. With a focus on advancing therapeutics for genetically driven muscle diseases, Dyne Therapeutics may be a compelling investment opportunity.
Sources:
– MarketBeat Ratings
– StockNews.com
– JPMorgan Chase & Co.
– Chardan Capital
– SEC Filings
– EcoR1 Capital LLC
– VR Adviser LLC
– State Street Corp
– Atlas Venture Life Science Advisors LLC
– Braidwell LP
– Dyne Therapeutics Company Profile